Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window

Current Osteoporosis Reports

Volumn 6, Issue 1, 2008, Pages 24-30

  Bilezikian, John P ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; FRAGILITY FRACTURE; HUMAN; HYPERCALCEMIA; INCIDENCE; MONOTHERAPY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; TREATMENT DURATION; DRUG COMBINATION;

BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; TERIPARATIDE;

EID: 44849121708     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0005-9     Document Type: Review

References (50)

1. Hodsman AB, Bauer DC, Dempster D, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
2. Canalis E, Giustina A, Bilezikian JP: Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
3. Dempster DW, Parisien M, Silverberg SJ, et al.: On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999, 84:1562-1566.
4. Girotra M, Rubin M, Bilezikian J: The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006, 7:113-121.
5. Jiang Y, Zhao JJ, Mitlak BH, et al.: Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
6. Sellmeyer DE, Black DM, Palermo L, et al.: Heterogeneity in skeletal response to full-length parathyroid hormone (PTH) in the treatment of osteoporosis. Osteoporos Int 2007, 18:973-979.
7. Burr DB, Hirano T, Turner CH, et al.: Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157-165.
8. Keaveny TM, Hoffman PE, Kepperdahl, et al.: Comparison of the effects of teriparatide and alendronate on parameters of total hip strength as assessed by finite element analysis [abstract]. J Bone Miner Res 2007, 22(Suppl 1):S26.
9. Borggrefe J, Graeff C, Nickelsen TN, et al.: Effects of 2 year teriparatide treatment on 3-D femoral neck bone distribution, geometry, and bone strength: Results from the EUROFORS study [abstract]. J Bone Miner Res 2007, 22(Suppl 1):S75.
10. Parfitt AM: Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17:1741-1743.
11. Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
12. Lindsay R, Silverman SL, Cooper C, et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320-323.
13. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
14. Gallagher JC, Genant HK, Crans GG, et al.: Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005, 90:1583-1587.
15. Marcus R, Wang O, Satterwhite J, Mitlak B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18-23.
16. Prince R, Sipos A, Hossain A, et al.: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005, 20:1507-1513.
17. Hodsman AB, Hanley DA, Ettinger MP, et al.: Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212-5220.
18. Fox J, Miller MA, Recker RR, et al.: Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: A study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 2005, 5:356-357.
19. Greenspan SL, Bone HG, Ettinger MP, et al.: Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 2007, 146:326-339.
20. Antoniucci DM, Sellmeyer DE, Bilezikian JP, et al.: Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab 2007, 92:942-947.
21. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
22. Orwoll ES, Scheele WH, Paul S, et al.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
23. Kaufman JM, Orwoll E, Goemaere S, et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2004, 16:510-516.
24. Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
25. Ettinger B, San Martin J, Crans G, Pavo I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
26. Cosman F, Nieves J, Zion M, et al.: Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575.
27. Miller P, Lindsay R, Watts N, et al.: Patients previously treated with risedronate demonstrate greater responsiveness to teriparatide than those previously treated with alendronate: The Optamise trial. J Bone Miner Res 2007, 22(Suppl 1):S26.
28. Delmas P, Watts N, Miller P, et al.: Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: The Optamise study. J Bone Miner Res 2007, 22(Suppl 1):S27.
29. Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
30. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
31. Deal C, Omizo M, Schwartz EN, et al.: Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebocontrolled trial. J Bone Miner Res 2005, 20:1905-1911.
32. Misof BM, Roschger P, Cosman F, et al.: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment. J Clin Endocrinol Metab 2003, 88:1150-1156.
33. Lindsay R, Scheele WH, Neer R, et al.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004, 164:2024-2030.
34. Kurland ES, Heller SL, Diamond B, et al.: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int 2004, 15:992-997.
35. Lindsay R, Nieves J, Formica C, et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
36. Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
37. Black DM, Bilezikian JP, Ensrud KE, et al.: One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005, 353:555-565.
38. Harper KD, Krege JH, Marcus R, Mitlak BH: Comments on initial experience with teriparatide in the United States. Curr Med Res Opin 2006, 22:1927.
39. Vahle JL, Long GG, Sandusky G, et al.: Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438.
40. Jimenez C, Kim W, Al Sagier F, et al.: Primary hyperparathyroidism and osteosarcoma: Examination of a large osteosarcoma cohort identifies unique characteristics. J Bone Miner Res 2003, 18(Suppl 2):LB6.
41. Tashjian AH Jr, Gagel RF: Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006, 21:354-365.
42. Harper KD, Krege JH, Marcus R, Mitlak BH: Osteosarcoma and teriparatide? J Bone Miner Res 2007, 22:334.
43. Levin G, Mazouz C: Transdermally-delivered PTH(1-34), a new treatment for osteoporotic patients: Results of phase I studies. J Bone Miner Res 2007, 22(Suppl 1):S324.
44. Horwitz MJ, Tedesco MB, Gundberg C, et al.: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:569-575.
45. Black DM, RoseI CJ: Parsimony with PTH: is a single weekly injection of PTH superior to a larger cumulative dose given daily? J Bone Miner Res 2002, 17(Suppl 1):SA367.
46. Ponnapakkam T, Matsushita O, Sakon J, Gensure RC: Weekly administration of a novel parathyroid hormone - collagen binding domain fusion protein increases bone mineral density by more than 15 percent in normal mice. J Bone Miner Res 2007, 22(Suppl 1):S64.
47. Cosman F, Nieves JW, Zion M, et al.: Effects of PTH rechallenge 1 year after the first PTH course in patients on long-term alendronate. J Bone Miner Res 2005, 20(Suppl 1):1079.
48. Gowen M, Stroup GB, Dodds RA, et al.: Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000, 105:1595-1604.
49. Ethgen D, Danoff T, Schultz M, et al.: Antagonism of calcium sensing receptor stimulates dose-related release of endogenous parathyroid hormone in normal volunteers: A proof of concept study. J Bone Miner Res 2007, 22(Suppl 1):S128.
50. Rubin MR, Bilezikian JP: New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 2003, 32:285-307.